Source: Eur Respir J 2016; 47:1568-1571
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ierodiakonou Despo, Portelli Michael A., Postma Dirkje S., Koppelman Gerard H., Gerritsen Jorrit, ten Hacken Nick H.T., Timens Wim, Boezen H. Marike, Vonk Judith M., Sayers Ian. Urokinase plasminogen activator receptor polymorphisms and airway remodelling in asthma. Eur Respir J 2016; 47:1568-1571

Member's Comments

No comment yet.

Related content which might interest you: Urokinase type plasminogen activator improves airway inflammation and mucin expression in a murine asthma model Source: Annual Congress 2010 - Mechanisms and modulation of allergic inflammation in the lung Year: 2010 The relation between plasminogen activator inhibitor-1 (PAI-1) and inflammatory markers in COPD: A possible risk factor of inflammation-induced thrombosis Source: International Congress 2017 – Systemic and airway biomarkers Year: 2017 Upregulation of the gene encoding the urokinase-type plasminogen activator (uPA) in respiratory muscles of COPD patients Source: Annual Congress 2004 - Skeletal muscle in respiratory disease Year: 2004 Soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in exacerbated COPD Source: International Congress 2018 – New predictors of morbidity and mortality in COPD Year: 2018 Enoxaparin reduced ventilation-induced plasminogen activator inhibitor-1 Source: Annual Congress 2009 - Crossing the line: alveolo-capillary barrier control in acute lung injury Year: 2009 Pro-urokinase up-regulates the expression of urokinase type plasminogen activator (u-PA) in human pulmonary arterial endothelial cells Source: Eur Respir J 2007; 30: Suppl. 51, 143s Year: 2007 The regulation of plasminogen activator inhibitor-1 (PAI-1) production with dexamethasone by human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Soluble urokinase-type plasminogen activator receptor in monitoring of treatment response in acute exacerbation of chronic obstructive pulmonary disease Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia Source: ERJ Open Res, 5 (1) 00212-2018; 10.1183/23120541.00212-2018 Year: 2019 Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 suppresses allergic asthma in a murine model Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010 Soluble urokinase plasminogen activator receptor (suPAR) is associated with COPD readmission and mortality Source: International Congress 2019 – Long-term lung function: from early birth to adulthood Year: 2019 LATE-BREAKING ABSTRACT: Molecular mechanisms of plasminogen activator inhibitor-1 elevation in COPD sputum Source: Annual Congress 2012 - Cell biology and inflammatory gene expression in chronic lung disease Year: 2012 The effect of prostaglandin (PG) E2 and its receptor antagonists on urokinase-type plasminogen activator (uPA) production by human lung fibroblasts Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 Regulation of plasminogen activator activity by inflammatory mediators in lung epithelial cells Source: Eur Respir J 2005; 26: Suppl. 49, 343s Year: 2005 SERPINE1 -675 4G/5G polymorphism is associated with asthma severity and inhaled corticosteroid response Source: Eur Respir J 2011; 38: 1036-1043 Year: 2011 Urokinase plasminogen activator receptor variants drive distinct phenotypes in the bronchial epithelium Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015 Lung fibroblasts regulate the urokinase-type plasminogen activator receptor (uPAR) expression of alveolar epithelial cells and endothelial cells Source: Eur Respir J 2006; 28: Suppl. 50, 397s Year: 2006 Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD Source: International Congress 2015 – Non-exhaled biomarkers in the assessment of airways disease Year: 2015 Relationship of circulating soluble urokinase plasminogen activator receptor (suPAR) levels to disease control in asthma and asthmatic pregnancy Source: International Congress 2014 – Systemic biomarkers for airway diseases Year: 2014